Welcome to Broken String Biosciences
Broken String Biosciences is at the forefront of enhancing the safety and efficacy of gene editing therapies to enable transformative therapeutics to become a safe reality for patients.
About the technology
INDUCE-seq™ is a game changing technology for the characterisation of genome breaks in cell & gene therapy applications.
Updates
-
Broken String Biosciences appoints Gavin Burns as Vice President of Quality and Operations
Cambridge, UK, 22 November 2023: Broken String Biosciences (“Broken String”), a genomics company that has built a technology platform to drive the development of cell and gene therapies that are safer by design, today announced the appointment of Gavin Burns, PhD, as Vice President of Quality and Operations. With an extensive background leading quality assurance in…
-
Broken String Biosciences’ INDUCE-seq platform demonstrates impact of structural DNA changes on specificity of CRISPR-Cas9 gene editing
Cambridge, UK, 18 October 2023: Broken String Biosciences (“Broken String”), a genomics company building a technology platform to drive the development of cell and gene therapies that are safer by design, today announced that its INDUCE-seq™ DNA break-mapping technology had been used in a peer-reviewed research paper to characterize off-target effects of CRISPR-Cas9 gene editing…
-
Broken String Biosciences strengthens senior leadership team to accelerate product development and commercialization
Cambridge, UK, 02 October 2023: Broken String Biosciences (“Broken String”), a genomics company building a technology platform to drive the development of cell and gene therapies that are safer by design, today announced the expansion of its senior leadership team with the appointments of Vincent Smith, PhD, as Chief Technology Officer and Jessica Rich as…
-
Broken String Biosciences Closes $15M Series A Funding Round
Cambridge, UK, 18 September 2023: Broken String Biosciences (“Broken String”), a genomics company building a technology platform to drive the development of cell and gene therapies that are safer by design, today announced that it has closed a $15 million Series A investment round, co-led by Illumina Ventures and Mérieux Equity Partners, with contributions from…
-
Broken String Biosciences joins Campus
Cell & gene therapies based on genome editing technologies such as CRISPR-Cas9 are positioned to become a new generation of transformative therapeutics, with the ability to correct disease at the genetic level. Because they directly alter our DNA and have the propensity to go ‘off-target’, assessing whether these therapies are safe for patients is extremely…
-
Genomics company Broken String Biosciences expands presence within the Cambridge cluster with new laboratory at Chesterford Research Park
Chesterford Research Park is delighted to welcome Broken String Biosciences to the Park’s eminent Science Village. Aiming to develop safer cell and gene therapies by assessing the stability of the genome, Broken String Biosciences is leveraging novel genomic sequencing approaches to build a technology platform that will drive the development of CRISPR cell and gene therapies that…
Meet the team
Our team operates at the intersection of biology, bioinformatics and data science.
